Schrödinger, Inc. (NASDAQ:SDGR) Shares Sold by Lazard Asset Management LLC

Lazard Asset Management LLC cut its holdings in Schrödinger, Inc. (NASDAQ:SDGR) by 1.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,210,861 shares of the company’s stock after selling 23,405 shares during the quarter. Lazard Asset Management LLC owned approximately 1.67% of Schrödinger worth $32,693,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC acquired a new stake in shares of Schrödinger in the fourth quarter valued at approximately $67,000. Russell Investments Group Ltd. lifted its stake in shares of Schrödinger by 22.7% during the first quarter. Russell Investments Group Ltd. now owns 218,564 shares of the company’s stock valued at $5,901,000 after buying an additional 40,434 shares during the period. Vanguard Group Inc. lifted its stake in shares of Schrödinger by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 6,776,631 shares of the company’s stock valued at $242,603,000 after buying an additional 77,830 shares during the period. Sumitomo Mitsui Trust Holdings Inc. lifted its stake in shares of Schrödinger by 60.3% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,300,750 shares of the company’s stock valued at $82,367,000 after buying an additional 865,867 shares during the period. Finally, Parkman Healthcare Partners LLC lifted its stake in shares of Schrödinger by 9.9% during the fourth quarter. Parkman Healthcare Partners LLC now owns 405,232 shares of the company’s stock valued at $14,507,000 after buying an additional 36,578 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Schrödinger Price Performance

SDGR stock traded up $0.13 during mid-day trading on Friday, hitting $22.42. 449,951 shares of the company were exchanged, compared to its average volume of 646,352. Schrödinger, Inc. has a twelve month low of $18.21 and a twelve month high of $52.81. The firm has a fifty day simple moving average of $21.21 and a 200 day simple moving average of $24.66.

Schrödinger (NASDAQ:SDGR) last posted its quarterly earnings results on Wednesday, May 1st. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.76). Schrödinger had a negative net margin of 75.94% and a negative return on equity of 29.25%. The company had revenue of $36.60 million for the quarter, compared to the consensus estimate of $41.23 million. As a group, research analysts anticipate that Schrödinger, Inc. will post -2.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on SDGR. Citigroup reduced their price objective on shares of Schrödinger from $39.00 to $37.00 and set a “buy” rating on the stock in a research note on Thursday, May 2nd. Leerink Partnrs raised shares of Schrödinger to a “strong-buy” rating in a research note on Tuesday, July 2nd. Craig Hallum reduced their price objective on shares of Schrödinger from $35.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, May 2nd. KeyCorp cut their price target on shares of Schrödinger from $30.00 to $25.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Finally, SVB Leerink initiated coverage on shares of Schrödinger in a research note on Tuesday, July 2nd. They set an “outperform” rating and a $29.00 price target on the stock. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Schrödinger has an average rating of “Moderate Buy” and an average price target of $38.90.

Schrödinger Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.